Cited by 165Lung Cancer Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsRadiomics and Machine Learning in Medical Imaging

The DOI matches its Crossref record; 42 of the 50 references it cites were found in a registry or an index.

Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index

Open access

Abstract

Introduction We compared primary non-small cell lung cancer (NSCLC) F-fluorodeoxyglucose (FDG) uptake at positron emission tomography (PET) to tumor histologic features and Ki-67 proliferation index. This large, prospectively-recruited patient cohort has previously been analyzed based on differences in FDG uptake across stage groups; the current analysis adds further dimensions to this characterization. Materials and methods One hundred seventy-eight patients with potentially-resectable NSCLC were scanned with FDG PET before therapy. A partial volume correction algorithm was used to correct FDG uptake values for their dependence on tumor size. Primary tumor resection specimens, core biopsies, and biopsies of metastatic lymph nodes were used to assess each tumor's NSCLC histologic subtype, degree of differentiation, and Ki-67 proliferation index. Results Bronchioalveolar carcinomas were found to have lower FDG uptake at PET and lower Ki-67 scores than any other histologic subtype. Non-bronchioalveolar adenocarcinomas had lower FDG uptake and Ki-67 scores than squamous cell carcinomas or large cell undifferentiated carcinomas. Better differentiated NSCLCs had lower FDG uptake and Ki-67 scores than more poorly differentiated NSCLCs. There was a significant positive correlation between FDG uptake and Ki-67 scores. Partial volume correction increased the strength of this correlation, while also diminishing the strong positive correlation between FDG uptake and tumor size. Conclusions There are significant differences in NSCLC FDG uptake across histologic subtypes and differentiation groups. These differences parallel nearly identical differences in Ki-67 scores, implying that differences in NSCLC tumor cell proliferation may give rise to commensurate differences in tumor glucose metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e31818307a7

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 2

  1. Rao, 2000, Prevalence of metastatic disease and impact of PET on management in staging lung cancer: a clinical series of 400 patients, J Nucl Med, 41, 75P
  2. Kohlmyer, 2000, Comparison of recovery coefficients for PET based on maximum and average ROI pixel values, Eur J Nuclear Med, 27, 977

Cited by

Sorted by citations

Items 101–165 of 165

Metadata

Authors
Vesselle, H., Salskov, A., Turcotte, E., Wiens, L., Schmidt, R., Jordan, C. D., Vallières, E., & Wood, D. E.
Affiliations
University of Washington (US)
Corresponding author
Vesselle, Hubert
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2008-09
Volume
3
Issue
9
Pages
971-978
ISSN
1556-0864 (ISSN-L)
OpenAlex
W1979039258
Cited by
165
References
50
Citations by year
2026: 3 · 2025: 3 · 2024: 6 · 2023: 9 · 2022: 13 · 2021: 9 · 2020: 9 · 2019: 4 · 2018: 16 · 2017: 7 · 2016: 10 · 2015: 8 · 2014: 13 · 2013: 10 · 2012: 13
FWCI
9.83
Type
journal article
Language
en
Open access
Locations
  • Journal of Thoracic Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Washington
  • National Cancer Institute (1R01 CA80907, R01CA115559, R01CA080907, R01CA107264)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
non-small cell lung cancer, FDG uptake, positron emission tomography, Ki-67 proliferation index, tumor histologic subtype, tumor differentiation, bronchioloalveolar carcinoma, adenocarcinoma, squamous cell carcinoma, tumor glucose metabolism, partial volume correction, tumor size
MeSH terms
Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Neoplasm Staging, Prognosis, Prospective Studies, Radiography, Thoracic, Tomography, X-Ray Computed, Biomarkers, Tumor, Cohort Studies, Carcinoma, Large Cell, Radiopharmaceuticals, Ki-67 Antigen, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review